Therapeutic Response Statement (Sensitivity) Deprecated

This therapeutic response statement Supports the relationship that EGFR activating variants status confers therapeutic sensitivity to Bevacizumab, Erlotinib in patients with Non-Small Cell Lung Cancer.

The Republic of Ireland's Health Service Executive (HSE) has approved bevacizumab in combination with erlotinib for reimbursement as a treatment option for the first-line treatment of adult patients with unresectable advanced, metastatic, or recurrent non-small cell lung cancer with EGFR activating variants.

This statement is based on a regulatory approval from the Health Service Executive:

In combination with erlotinib is indicated for the first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous cell lung cancer with Epidermal Growth Factor (EGFR) activating mutations

Citation

Bevacizumab 15mg/kg Therapy - 21 days, 2026, version number 7, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6556/215_V6a_Bevacizumab_15.pdf

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2018-11-22	Health Service Executive	Indication approved for reimbursement.